TY - JOUR T1 - Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2 JF - medRxiv DO - 10.1101/2020.12.15.20248264 SP - 2020.12.15.20248264 AU - Douglas F. Lake AU - Alexa J. Roeder AU - Erin Kaleta AU - Paniz Jasbi AU - Sivakumar Periasamy AU - Natalia Kuzmina AU - Alexander Bukreyev AU - Thomas Grys AU - Liang Wu AU - John R Mills AU - Kathrine McAulay AU - Maria Gonzalez-Moa AU - Alim Seit-Nebi AU - Sergei Svarovsky Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/05/2020.12.15.20248264.abstract N2 - As increasing numbers of people recover from and are vaccinated against COVID-19, tests are needed to measure levels of protective, neutralizing antibodies longitudinally to help determine duration of immunity. We developed a lateral flow assay (LFA) that measures levels of neutralizing antibodies in plasma, serum or whole blood. The LFA is based on the principle that neutralizing antibodies inhibit binding of the spike protein receptor-binding domain (RBD) to angiotensin-converting enzyme 2 (ACE2). The LFA compares favorably with authentic SARS-CoV-2 and pseudotype neutralization assays with an accuracy of 98%. Sera obtained from patients with seasonal coronaviruses did not prevent RBD from binding to ACE2. To demonstrate the usefulness of the LFA for measuring antibodies in convalescent plasma used for therapy, we measured conversion of non-immune plasma into strongly neutralizing plasma. This is the first report of a neutralizing antibody test that is rapid, highly portable and relatively inexpensive that might be useful in assessing COVID-19 vaccine-induced immunity.Competing Interest StatementAJR, EK, PJ, SP, NK, AB, TG, LW, JRM and KM have no competing interests. DFL received support from Axim Biotechnologies to perform the study. SS and AS-N are supported and employed by Axim Biotechnologies.Funding StatementAxim Biotechnologies supported this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Peripheral blood, serum and plasma were collected for this study under an Arizona State University IRB approved protocol #0601000548 and Mayo Clinic IRB protocol #20-004544.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the manuscript is available. ER -